Human CFHR5 ELISA Kit (V2LY-0626-LY4438)

Go to compare Compare Online Inquiry
Tested Data
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
0.14 ng/mL
Detection Range
0.3-90 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
64.4 kDa
Components
  • Pre-coated ELISA Plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
Complement Factor H Related 5
Function
Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH.
Biological Process
Complement activation, alternative pathway Source: UniProtKB
Cytolysis by host of symbiont cells Source: UniProtKB
Negative regulation of protein binding Source: UniProtKB
Regulation of complement activation Source: Reactome
Cellular Location
Secreted
Involvement in disease
Defects in CFHR5 have been found in patients with atypical hemolytic uremic syndrome and may contribute to the disease. Atypical hemolytic uremic syndrome is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
CFHR5 deficiency (CFHR5D): A progressive disease characterized by glomerulonephritis, hematuria, renal failure, end-stage renal disease, subendothelial and mesangial glomerular C3 deposits, mesangial matrix expansion, increased glomerular cellularity, and segmental capillary wall thickening. Hematuria may become apparent after respiratory infections.

Gómez Delgado, I., Gutiérrez-Tenorio, J., Fraga Rodríguez, G. M., Cavero, T., Arjona, E., & Sánchez-Corral, P. (2021). Low factor H-related 5 levels contribute to infection-triggered haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clinical Kidney Journal, 14(2), 707-709.

Malik, T. H., Gitterman, D. P., Lavin, D. P., Lomax-Browne, H. J., Hiemeyer, E. C., Moran, L. B., ... & Pickering, M. C. (2021). Gain-of-function factor H–related 5 protein impairs glomerular complement regulation resulting in kidney damage. Proceedings of the National Academy of Sciences, 118(13).

Lorés-Motta, L., van Beek, A. E., Willems, E., Zandstra, J., van Mierlo, G., Einhaus, A., ... & den Hollander, A. I. (2021). Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. The American Journal of Human Genetics, 108(8), 1367-1384.

Kadkhodayi-Kholghi, N., Bhatt, J. S., Gor, J., McDermott, L. C., Gale, D. P., & Perkins, S. J. (2020). The solution structure of the complement deregulator FHR5 reveals a compact dimer and provides new insights into CFHR5 nephropathy. Journal of Biological Chemistry, 295(48), 16342-16358.

Hu, X., Liu, H., Du, J., Chen, Y., Yang, M., Xie, Y., ... & Gong, Z. (2019). The clinical significance of plasma CFHR 1–5 in lupus nephropathy. Immunobiology, 224(3), 339-346.

Medjeral-Thomas, N. R., Moffitt, H., Lomax-Browne, H. J., Constantinou, N., Cairns, T., Cook, H. T., & Pickering, M. C. (2019). Glomerular Complement Factor H–Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. Kidney international reports, 4(10), 1387-1400.

Zhu, L., Guo, W. Y., Shi, S. F., Liu, L. J., Lv, J. C., Medjeral-Thomas, N. R., ... & Zhang, H. (2018). Circulating complement factor H–related protein 5 levels contribute to development and progression of IgA nephropathy. Kidney international, 94(1), 150-158.

Zhang, P., Zhu, M., Geng‐Spyropoulos, M., Shardell, M., Gonzalez‐Freire, M., Gudnason, V., ... & Semba, R. D. (2017). A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CFH) variants and CFH‐related proteins 1–5 in human plasma. Proteomics, 17(6), 1600237.

Togarsimalemath, S. K., Sethi, S. K., Duggal, R., Le Quintrec, M., Jha, P., Daniel, R., ... & Dragon-Durey, M. A. (2017). A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney international, 92(4), 876-887.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human CFHR5 ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.